This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n20http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/chebi/
n7http://linked.opendata.cz/resource/mesh/concept/
n28http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/wikipedia/
n18http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/pharmgkb/
n12http://www.rxlist.com/
n27http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/bindingdb/
n24http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/patent/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n25http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/drugbank/
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB05521/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n5http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05521
rdf:type
n3:Drug
n3:description
Telaprevir (VX-950) is a highly selective and potent inhibitor of the HCV NS3-4A serine protease. It is a member of a class of antiviral drugs known as protease inhibitors and is the first hepatitis C drug that has demonstrated activity in patients who have failed prior therapy. On April 28, 2011, the FDA Antiviral Drugs Advisory Committee voted 18-0 to recommend approval telaprevir for people with genotype 1 chronic hepatitis C and was approved in the U.S. in May, 2011.
n3:dosage
n28:271B45A5-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Kim JJ, Culley CM, Mohammad RA: Telaprevir: An oral protease inhibitor for hepatitis C virus infection. Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22180548 # Liu-Young G, Kozal MJ: Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS. 2008 Jun;22(6):449-57. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18479202 # Forestier N, Zeuzem S: Telaprevir for the treatment of hepatitis C. Expert Opin Pharmacother. 2012 Mar;13(4):593-606. doi: 10.1517/14656566.2012.660524. Epub 2012 Feb 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22332992 # Garg V, Kauffman RS, Beaumont M, van Heeswijk RP: Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012;17(7):1211-21. doi: 10.3851/IMP2356. Epub 2012 Sep 7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22954756
n3:group
approved
n3:halfLife
The mean elimination half-life after single-dose oral administration of telaprevir 750 mg typically ranged from about 4.0 to 4.7 hours. At steady state, the effective half-life is about 9 to 11 hours.
n3:indication
Treating chronic hepatitis C virus (genotype 1) infection in patients with compensated liver (due to liver diseases like cirrhosis) that are treatment naive or have failed therapy with interferons (either null or partial responders and treatment relapsers).
owl:sameAs
n10:DB05521 n27:DB05521
dcterms:title
Telaprevir
adms:identifier
n17:51167-100-01 n18:PA165958354 n19:68595 n20:2279948 n21:Telaprevir n22:DB05521 n23:50212208 n24:3010818 n25:D09012
n3:mechanismOfAction
Telaprevir is an inhibitor of the HCV NS3/4A serine protease, necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS4A, NS4B, NS5A and NS5B proteins and essential for viral replication. It belongs to the chemical class of alpha-ketoamids and binds to NS3/4A in a covalent but reversible manner.
n3:patent
n15:7820671
n3:routeOfElimination
Following administration of a single oral dose of 750 mg 14C-telaprevir in healthy subjects, 90% of total radioactivity was recovered in feces, urine and expired air within 96 hours post-dose. The median recovery of the administered radioactive dose was approximately 82% in the feces, 9% in exhaled air and 1% in urine. The contribution of unchanged 14C-telaprevir and the R-diastereomer of telaprevir towards total radioactivity recovered in feces was 31.9% and 18.8%, respectively.
n3:synonym
(1S,3AR,6as)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide MP-424 VX 950 Incivek VX-950
n3:toxicity
The highest documented dose administered is 1875 mg every 8 hours for 4 days in healthy subjects with telaprevir alone. In that study, the following common adverse events were reported more frequently with the 1875 mg q8h regimen compared to the 750 mg q8h regimen: nausea, headache, diarrhea, decreased appetite, dysgeusia, and vomiting. The two most common adverse events that caused the discontinuation of treatment are anemia and rash.
n3:volumeOfDistribution
Apparent volume of distribution (Vd/F) = 252 L. This large volume of distribution suggests extensive penetration into tissues.
n4:hasAHFSCode
n14:8-18-40
n3:foodInteraction
St. John's wort is a CYP3A4 inducer which will decrease levels of telaprevir.
n3:proteinBinding
59% to 76% and binds to alpha 1-acid glycoprotein and albumin in a concentration dependent manner.
n3:synthesisReference
Znabet A, Polak MM, Janssen E, de Kanter FJ, Turner NJ, Orru RV, Ruijter E. A highly efficient synthesis of telaprevir by strategic use of biocatalysis and multicomponent reactions. Chem Commun (Camb). 2010 Nov 14;46(42):7918-20. Epub 2010 Sep 20.
n6:hasConcept
n7:M0466818
foaf:page
n12:incivek-drug.htm n13:telaprevir.html
n3:IUPAC-Name
n8:271B45AA-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B45B0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B45AF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B45AC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B45AD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B45AE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B45C0-363D-11E5-9242-09173F13E4C5 n8:271B45A8-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B45A6-363D-11E5-9242-09173F13E4C5 n8:271B45A9-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B45A7-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n5:J05AE11
n3:H-Bond-Acceptor-Count
n8:271B45B6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B45B7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B45B1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B45B2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B45B4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B45B3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B45B5-363D-11E5-9242-09173F13E4C5
n3:absorption
Telaprevir is orally available, most likely absorbed in the small intestine, with no evidence for absorption in the colon. Maximum plasma concentrations after a single dose of telaprevir are generally achieved after 4 to 5 hours. In vitro studies performed with human Caco-2 cells indicated that telaprevir is a substrate of P-glycoprotein (P-gp). Exposure to telaprevir is higher during co-administration of peginterferon alfa and ribavirin than after administration of telaprevir alone. Dissolution of telaprevir is not dependent by pH.
n3:affectedOrganism
Hepatitis C virus, RSV and other RNA/DNA viruses
n3:casRegistryNumber
402957-28-2
n3:clearance
After oral administration, the apparent total clearance (Cl/F) was estimated to be 32.4 L/h with an inter-individual variability of 27.2%.
n3:Bioavailability
n8:271B45BC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B45BE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B45BF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B45BB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B45BA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B45BD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B45AB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B45B8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B45B9-363D-11E5-9242-09173F13E4C5